MAPK1 and melanoma: Given its specificity for ERK and the potential for ERK inhibition to inhibit both MAPK and PI3K/AKT pathways, we evaluated the susceptibility of wild-type, mutant BRAF- or NRAS-melanoma, and BRAF-mutant melanoma with acquired BRAFi resistance.